Spectrum Pharmaceutecals Inc (SPPI)

[Tartiaboy]

Having two agents that attack the same receptor may be a problem. T-DM1 and Pozi both would hit the HER2 receptor on cancer and non-cancer cells. I don't recall seeing that many drug combination that hit the same target especially wherein they were both individually toxic to non-cancer cells. SO, I agree that toxicity could have been an issue.

I still think that MDACC and SPPI are looking for non-HER2 and non-EGFR targeting drugs as the companion drugs with Pozi. I know that Heymach likes Bevacizumab, but not sure what other candidates they have.

I also don't know if the phase I T-DM1 + Pozi trial in mBC would have given them any useful data for the exon20 trials.

As you said, we will learn more in 2H.

Up next is getting a PDUFA data for Rolontis.